Effects of Intravitreal Injection on Ocular Surface and Anterior Segment Parameters

Overview

Journal Beyoglu Eye J

Publisher Kare Publishing

Specialty Ophthalmology

Date 2022 Jan 10

PMID 35005499

Authors

Hafize Gokben Ulutas

Neslihan Parmak Yener

Affiliations

Soon will be listed here.

Abstract

Objectives: This study was designed to investigate the long-term effects of intravitreal anti-vascular endothelial growth factor (VEGF) injections on ocular surface and anterior segment parameters. A comparison was performed of the treated eye and the fellow healthy eye.

Methods: The study group included patients who had received at least 3 intravitreal injections of anti-VEGF agents (bevacizumab, ranibizumab, or aflibercept) for retinal vascular disorders. All of the subjects were treated in only 1 eye. A complete ophthalmological examination, including evaluation of tear break-up time (TBUT), the Schirmer 1 test, the Oxford Grading Scale, and the Ocular Surface Disease Index (OSDI) questionnaire, corneal topography, and specular microscopy were performed in both eyes 1 month after the last injection.

Results: In this study, 49 eyes of 49 patients who underwent regular intravitreal injection in 1 eye were enrolled. The mean age was 63.85±9.8 years (range: 29-86 years). A mean of 4.06±1.7 (range: 3-11) injections were administered. There was no significant difference in the intraocular pressure, TBUT, Schirmer 1, fluorescein staining, or specular microscopy parameters (p>0.05). The mean non-invasive TBUT first and average values; the central, thinnest, and apex corneal thickness measurements; the anterior chamber depth, irido-corneal angle, corneal volume, and keratometry values were similar in each individual (p>0.05 for all parameters). The mean OSDI score was 27.5±17.6 for the injected eyes and 15.9±12.9 for the non-injected eyes (p<0.0001).

Conclusion: Intravitreal anti-VEGF injections had no effect on ocular surface, corneal endothe-lium, and anterior segment parameters.

Citing Articles

Ocular surface morbidity related to vitreoretinal interventions.

Vanathi M Indian J Ophthalmol. 2024; 72(6):767-768.

PMID: 38804794 PMC: 11232853. DOI: 10.4103/IJO.IJO_1154_24.

Evaluation of the effect of intravitreal injections on corneal epithelial, scleral and limbal region changes in diabetic retinopathy by AS-OCT.

Cinar A, Kupeli Cinar A, Guclu H Int Ophthalmol. 2024; 44(1):31.

PMID: 38329554 DOI: 10.1007/s10792-024-02947-8.

Ocular surface changes following vitreoretinal procedures.

Venkatesh R, Jayadev C, Mangla R, Chitturi S, Mohan S, Ratra D Indian J Ophthalmol. 2023; 71(4):1123-1126.

PMID: 37026243 PMC: 10276746. DOI: 10.4103/IJO.IJO_2573_22.

References

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Calonge M, Enriquez-de-Salamanca A, Diebold Y, Gonzalez-Garcia M, Reinoso R, Herreras J . Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm. 2010; 18(4):244-53. DOI: 10.3109/09273941003721926. View

Dohlman T, Lertsuwanroj B, DAmico D, Ciralsky J, Kiss S . Evaluation of signs and symptoms of ocular surface disease after intravitreal injection. Acta Ophthalmol. 2019; 97(8):e1154-e1156. DOI: 10.1111/aos.14146. View

Alkin Z, Perente I, Altan C, Konstantinidis A, Ozkaya A, Yuksel K . Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab-triamcinolone acetate combination. Eur J Ophthalmol. 2013; 23(4):504-9. DOI: 10.5301/ejo.5000241. View

Campbell R, Bronskill S, Bell C, Paterson J, Whitehead M, Gill S . Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol. 2010; 128(3):359-62. DOI: 10.1001/archophthalmol.2010.19. View

Zhang R, Park M, Richardson A, Tedla N, Pandzic E, de Paiva C . Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease. Ocul Surf. 2019; 18(1):158-169. DOI: 10.1016/j.jtos.2019.11.006. View

Simone J, Whitacre M . Effects of anti-inflammatory drugs following cataract extraction. Curr Opin Ophthalmol. 2001; 12(1):63-67. DOI: 10.1097/00055735-200102000-00011. View

Li X, Hu L, Hu J, Wang W . Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007; 26(9 Suppl 1):S16-20. DOI: 10.1097/ICO.0b013e31812f67ca. View

. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5(2):75-92. DOI: 10.1016/s1542-0124(12)70081-2. View

10.

Guzel H, Bakbak B, Koylu M, Gonul S, Ozturk B, Gedik S . The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema. Cutan Ocul Toxicol. 2016; 36(1):5-8. DOI: 10.3109/15569527.2016.1140177. View

11.

Faragher R, Mulholland B, Tuft S, Sandeman S, Khaw P . Aging and the cornea. Br J Ophthalmol. 1998; 81(10):814-7. PMC: 1722015. DOI: 10.1136/bjo.81.10.814. View

12.

Miljanovic B, Dana R, Sullivan D, Schaumberg D . Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007; 143(3):409-15. PMC: 1847608. DOI: 10.1016/j.ajo.2006.11.060. View

13.

Brown D, Kaiser P, Michels M, Soubrane G, Heier J, Kim R . Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-44. DOI: 10.1056/NEJMoa062655. View

14.

Ozcura F, Aydin S, Helvaci M . Ocular surface disease index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm. 2007; 15(5):389-93. DOI: 10.1080/09273940701486803. View

15.

Ridder 3rd W, Oquindo C, Dhamdhere K, Burke J . Effect of Povidone Iodine 5% on the Cornea, Vision, and Subjective Comfort. Optom Vis Sci. 2017; 94(7):732-741. DOI: 10.1097/OPX.0000000000001091. View

16.

Baudouin C, Labbe A, Liang H, Pauly A, Brignole-Baudouin F . Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29(4):312-34. DOI: 10.1016/j.preteyeres.2010.03.001. View

17.

Ghasemi Falavarjani K, Nguyen Q . Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013; 27(7):787-94. PMC: 3709385. DOI: 10.1038/eye.2013.107. View

18.

Arslan G, Guven D, Alkan A, Kacar H, Demir M . Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure. Cutan Ocul Toxicol. 2019; 38(4):344-348. DOI: 10.1080/15569527.2019.1616749. View

19.

Kerimoglu H, Ozturk B, Bozkurt B, Okka M, Okudan S . Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection?. Acta Ophthalmol. 2009; 89(2):138-42. DOI: 10.1111/j.1755-3768.2009.01656.x. View

20.

Bron A, Evans V, Smith J . Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003; 22(7):640-50. DOI: 10.1097/00003226-200310000-00008. View